Phase II study of S-1 chemotherapy in elderly patients with advanced non-small cell lung cancer harboring no EGFR gene mutation

Phase II study of S-1 chemotherapy in elderly patients with advanced non-small cell lung cancer harboring no EGFR gene mutation - Phase II study of S-1 chemotherapy in elderly patients with advanced non-small cell lung cancer harboring no EGFR gene mutation (ALCSG 1002)

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000005058

Enrollment

Registered

2011-02-14

Start date

2011-02-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-small cell lung cancer

Interventions

single agent S-1

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Eligibility includes; 1) patients having a histological or cytological diagnosis of NSCLC, 2) NSCLC at clinical stage IIIA to IV, 3) patients aged 70 and over 70 years, 4) an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, 5) patients having adequate organ function, 6) no prior chemotherapy for NSCLC, 7) NSCLC harboring no EGFR gene mutation, 8) life expectancy of longer than 3 months.

Exclusion criteria

Exclusion criteria: Patients are excluded if they have; 1) severe concomitant diseases, 2) interstitial pneumonia, 3) NSCLC with EGFR gene mutations, 4) no measurable lesion.

Design outcomes

Primary

Measure	Time frame
Response rate.	—

Secondary

Measure	Time frame
Disease control rate, overall survival, progression free survival, safety.	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026